Skip to main content

Table 1 Characteristics of case-control studies for lung cancer and IGF-I and IGFBP-3

From: IGF-I and IGFBP-3 and the risk of lung cancer: A meta-analysis based on nested case-control studies

Study Year, location Sample size
(case/control)
Measurement OR(95%CI) for IGF-I OR(95%CI) for IGFBP-3 Adjusted factors in the model in original report
    IGF-1 IGFBP3    
Lukanova et al.[14] 2001, USA 93/186 RIA RIA 0.54(0.14–2.07) 0.90(0.28–2.85) Age, date of recruitment in the study, menopausal status, current smoking, time since last meal, cotinine and BMI
London et al.[15] 2002, China 230/740 RIA IRMA 0.86(0.47–1.57) 0.50(0.25–1.02) Smoking
Spitz et al.[16] 2002, USA 159/297 ELISA ELISA 0.64(0.31–1.33) 2.35(1.13–4.92) Age, sex, race, year of enrollment, and year of blood draw, BMI, smoking status, pack-years of smoking, exposure population
Waikai et al.[17] 2002, Japan 194/9351 IRMA IRMA 1.74(1.08–2.81) 0.67(0.45–1.01) Age, area, gender, smoking habits, and BMI
Ahn et al.[18] 2006, Finland 200/400 ELISA ELISA 0.76(0.39–1.49) 0.71(0.35–1.47) Age, intervention arm, BMI, and years of smoking
Morris et al. [19] 2006, British 167/498 ELISA ELISA 1.21(0.62–2.35) 1.70(0.87–3.30) Age, smoking
  1. All are nested case-control studies within cohort study.
  2. BMI indicates body mass index.
  3. IRMA, immunoradiometric assay; ELISA, enzyme-linked immunoabsorbent assay; RIA, radioimmunoassay assay.